1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

 
• By Mandy Jackson

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.

MR image of Human brain

Biogen and Eisai Co. Ltd. will continue to test anti-amyloid agents in the treatment of Alzheimer's disease even after the failure of their most advanced and highest-profile candidate aducanumab in Phase III, but suggestions that Biogen should focus its resources elsewhere are mounting after this latest setback.

The partners said on March 21 that they will discontinue the Phase III ENGAGE and EMERGE clinical trials testing aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and in patients with mild Alzheimer's disease dementia based on a futility analysis by an independent

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from R&D